Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma

BİRBEN, ESRA; SAHINER, Umit

doi:10.55730/1300-0144.5569

Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma

Esra BİRBEN, (Hacettepe Üniversitesi, Fen Fakültesi, Biyoloji Bölümü, Ankara, Türkiye)

Ümit Murat ŞAHINER (Hacettepe Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Medical Sciences

10 2

Yıl: 2023 Cilt: 53 Sayı: 1 Sayfa Aralığı: 160 - 170 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5569 İndeks Tarihi: 24-03-2023

Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma

Öz:

Background/aim: Advanced glycation end products receptor (RAGE) is a pattern recognition receptor which attracted attention in chronic airway diseases recently. This study aimed to determine the association of RAGE with asthma and the cellular responses resulting from RAGE signaling pathway activation. Materials and methods: Asthmatic (n = 362) and healthy (n = 134) children were genotyped by PCR-RFLP. Plasma sRAGE levels were determined by ELISA. Lung structural cells were stimulated with AGEs (advanced glycation end products) and control BSA. Expressions of cytokines and protein levels were determined by real-time PCR and ELISA. Results: Gly82Ser and –374 T/A polymorphisms in RAGE gene were associated with lower plasma sRAGE levels (p < 0.001 and p < 0.025, respectively). AGE stimulation increased the expression of RAGE (p = 0.002), ICAM-1 (p = 0.010) and VCAM-1 (p = 0.002) in endothelial cells; TIMP-1 (p = 0.003) and MCP-1 (p = 0.005) in fibroblasts. AGE stimulation increased protein levels of IL-6 (p < 0.001) in endothelial cells; VEGF (p = 0.025) and IL-8 (p < 0.001) in fibroblasts; IL-1b (p < 0.001) and VEGF (p = 0.007) in epithelial cells. Conclusion: Activation of RAGE pathway may contribute to asthma pathogenesis by increasing the expression of several asthma- related genes. These findings suggest that suppression of RAGE signaling may be an alternative candidate for treating asthma.

Anahtar Kelime: Asthma airway cells angiogenesis RAGE remodeling

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. KleinJan A. Airway inflammation in asthma: key players beyond the Th2 pathway. Current Opinion in Pulmonary Medicine 2016; 22: 46-52. https://doi.org/10.1097/MCP.0000000000000224
2. Liu L, Poon R, Chen L, Frescura AM, Montuschi P et al. Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic children. Environmental Health Perspectives 2009; 117: 668–674. https://doi.org/10.1289/ehp11813
3. Milutinovic PS, Alcorn JF, Englert JM, Crum LT, Oury TD. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. American Journal of Pathology 2012; 181 (4): 1215-1225. https://doi.org/10.1016/j. ajpath.2012.06.031
4. Oczypok EA, Milutinovic PS, Alcorn JF, Khare A, Crum LT et al. Pulmonary receptor for advanced glycation end- products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells. Journal of Allergy and Clinical Immunology 2015; 136 (3): 747-756. https://doi.org/10.1016/j.jaci.2015.03.011
5. Zhang F, Su X, Huang G, Xin XF, Cao EH et al. sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells. Scienctific Reports 2017; 7 (1): 1-12. https://doi.org/10.1038/s41598-017-14667-4
6. Perkins TN, Oczypok EA, Dutz RE, Donnell ML, Myerburg MM et al. The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs. Journal of Allergy and Clinical Immunology 2019; 44 (3): 796- 808.e12. https://doi.org/10.1016/j.jaci.2019.03.019
7. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Advances in Pharmacology 1992; 23: 1-34. https://doi.org/10.1016/s1054- 3589(08)60961-8
8. Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends in Cardiovascular Medicine 1997; 7 (2): 39-47. https://doi. org/10.1016/S1050-1738(96)00137-5
9. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D et al. Tobacco smoke is a source of toxic reactive glycation products. Proceedings of the National Academy of Sciences U S A 1997; 94 (25): 13915-13920. https://doi.org/10.1073/ pnas.94.25.13915
10. Baynes JW. The Maillard hypothesis on aging: time to focus on DNA. Annals of the New York Academy of Sciences 2002; 959: 360-367. https://doi.org/10.1111/j.1749-6632.2002.tb02107 https://yonetim.trdizin.gov.tr/#/publication/create?journalissue=70949:~:text=11.%20Yamagishi%20S,10.4049/jimmunol.179.6.4053
11. Yamagishi S, Adachi H, Takeuchi M, Enomoto M, Furuki K et al. Serum level of advanced glycation end-products (AGEs) is anindependent determinant of plasminogen activator inhibitor-1 (PAI-1) innondiabetic general population. Hormone and Metabolic Research 2007; 39 (11): 845-848. https://doi.org/10.1055/s-2007-991176
12. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Current Pharmaceutical Design 2008; 14 (10): 953-961. https://doi. org/10.2174/138161208784139774
13. Ruan BH, Li X, Winkler AR, Cunningham KM, Kuai J et al. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor foradvanced glycation end product-dependent manner. The Journal of Immunology 2010; 185 (7): 4213-4222. https://doi.org/10.4049/ jimmunol.1000863
14. Lund T, Svindland A, Pepaj M, Jensen AB, Berg JP et al. Fibrin(ogen) may be an important target for methylglyoxal- derived AGE modification in elastic arteries of humans. Diabetes and Vascular Disease Research 2011; 8(4): 284-294. https://doi.org/10.1177/1479164111416831
15. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998; 47 (7): 1155-1157. https://doi. org/10.2337/diabetes.47.7.1155
16. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50 (6): 1505-1511. https://doi.org/10.2337/diabetes.50.6.1505
17. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes and Immunity 2002; 3 (3): 123- 135. https://doi.org/10.1038/sj.gene.6363861
18. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. European Respiratory Journal 2012; 39 (3): 721-729. https://doi.org/10.1183/09031936.00022011
19. Egron C, Roszyk L, Rochette E, Jabaudon M, Sapin V et al. Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases. Pediatric Pulmonology 2018; 53 (10): 1429-1435. https://doi. org/10.1002/ppul.24141
20. Shim EJ, Chun E, Lee HS, Bang BR, Kim TW et al. The role of high-mobility group box-1 (HMGB1) in the pathogenesis of asthma. Clinical and Experimental Allergy 2012; 42 (6): 958– 965. https://doi.org/10.1111/j.1365-2222.2012.03998.x
21. https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA- 2017-main-report-final_V2.pdf
22. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yılmaz Y et al. The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Archives of Medical Research 2008; 39 (3): 320-325. https://doi.org/10.1016/j.arcmed.2007.11.003
23. Chiu HC, Fu MM, Yang TS, Fu E, Chiang CY et al. Effect of high glucose, Porphyromonas gingivalis lipopolysaccharide and advanced glycation end-products on production of interleukin-6/-8 by gingival fibroblasts. Journal of Periodontal Research 2017; 52 (2): 268-276. https://doi.org/10.1111/ jre.12391
24. Tanaka K, Yamagata K, Kubo S, Nakayamada S, Sakata K et al. Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. Bone 2019; 128: 115034. https://doi. org/10.1016/j.bone.2019.115034
25. Jang EJ, Baek SE, Kim EJ, Park SY, Kim CD. HMGB1 enhances AGE-mediated VSMC proliferation via an increase in 5-LO- linked RAGE expression. Vascular Pharmacology 2019; 118- 119: 106559. https://doi.org/10.1016/j.vph.2019.04.001
26. Han X, Ma W, Zhu Y, Sun X, Liu N. Advanced glycation end products enhance macrophage polarization to the M1 phenotype via the HIF-1α/PDK4 pathway. Molecular and Cellular Endocrinology 2020; 514: 110878. https://doi. org/10.1016/j.mce.2020.110878
27. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circulation Research 2010; 106: 842–853. https:// doi.org/10.1161/CIRCRESAHA.109.212217
28. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R et al. ICAM- 1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005; 106 (2): 584–592. https://doi.org/10.1182/ blood-2004-12-4942
29. Lawson C and Wolf S. ICAM-1 signaling in endothelial cells. Pharmacological Reports 2009; 61 (1): 22–32. https://doi. org/10.1016/s1734-1140(09)70004-0
30. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE a mechanism for amplification of inflammatory responses. Circulation 2002; 105 (7): 816– 822. https://doi.org/10.1161/hc0702.104183
31. Hirose A, Tanikawa T, Mori H, Okada Y, Tanaka Y. Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. Federation of European Biochemical Societies (FEBS) Letter 2010; 584: 61–
66. https://doi.org/10.1016/j.febslet.2009.11.082 32. Dienz O and Rincon M. The effects of IL-6 on CD4 T cell responses. Clinical Immunology 2009; 130: 27–33. https://doi. org/10.1016/j.clim.2008.08.018
33. van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I et al. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. The American Journal of Physiology-Cell Physiology 2003; 285 (2): C343-C352. https://doi.org/10.1152/ajpcell.00048.2003
34. Allingham MJ, van Buul JD, Burridge K. ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. The Journal of Immunology 2007; 179 (6): 4053- 4064. https://doi.org/10.4049/jimmunol.179.6.4053
35. DeLeon-Pennell KY, Barker TH, Lindsey ML. Fibroblasts: The arbiters of extracellular matrix remodeling. Matrix Biology 2020; 91-92: 1–7. https://doi.org/10.1016/j.matbio.2020.05.006
36. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002; 39: 258–263. https://doi.org/10.1161/ hy0202.103268
37. Yue B. Biology of the extracellular matrix: an overview. Journal of Glaucoma 2014; 23: S20–S23. https://doi.org/10.1097/ IJG.0000000000000108
38. Hough KP, Curtiss ML, Blain TJ, Liu RM, Trevor J et al. Airway Remodeling in Asthma. Frontiers in Medicine 2020; 7: 191- 207. https://doi.org/10.3389/fmed.2020.00191
39. Mauad T, Silva LF, Santos MA, Grinberg L, Bernardi FD et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. American Journal of Respiratory and Critical Care Medicine 2004; 170 (8): 857–862. https://doi.org/10.1164/rccm.200403-305OC
40. de Medeiros Matsushita M, da Silva LF, dos Santos MA, Fernezlian S, Schrumpf JA et al. Airway proteoglycans are differentially altered in fatal asthma. The Journal of Pathology 2005; 207 (1): 102–110. https://doi.org/10.1002/path.1818
41. Van Doren SR. Matrix metalloproteinase interactions with collagen and elastin. Matrix Biology 2015; 44-46: 224–231. https://doi.org/10.1016/j.matbio.2015.01.005
42. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000; 2 (10): 737– 744. https://doi.org/10.1038/35036374
43. Gupta A, Zhou C, Chellaiah M. Osteopontin and MMP9: associations with VEGF expression/secretion and angiogenesis in PC3 prostate cancer cells. Cancers. 2013; 5: 617–638. https:// doi.org/10.3390/cancers5020617
44. Lee KS, Min KH, Kim SR, Park SJ, Park HS et al. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. American Journal of Respiratory and Critical Care Medicine 2006; 174: 161–170. https://doi.org/10.1164/rccm.200510-1558OC
45. Chaudhuri R, McSharry C, Brady J, Grierson C, Messow CM et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma. European Respiratory Journal 2014; 44 (4): 895-904. https://doi. org/10.1183/09031936.00047014
46. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clinica Chimica Acta 2010; 411 (21-22): 1570-1579. https://doi.org/10.1016/j.cca.2010.07.006
47. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40. https://doi.org/10.1182/blood.V96.1.34
48. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein- 1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105 (4): 1405-1407. https://doi. org/10.1182/blood-2004-08-3178
49. Osei ET, Brandsma CA, Timens W, Heijink IH, Hackett TL. Current perspectiveson the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. European Respiratory Journal 2020; 55 (2):1900563-1900579. https://doi. org/10.1183/13993003.00563-2019
50. Thomas SS, Chhabra SK. A study on the serum levels of interleukin-1beta in bronchial asthma. Journal of Indian Medical Association 2003; 101: 282-286.
51. Busse PJ, Birmingham JM, Calatroni A, Manzi J, Goryachokovsky A et al. Effect of aging on sputum inflammation and asthma control. Journal of Allergy and Clinical Immunology 2017; 139 (6): 1808-1818.e6. https://doi.org/10.1016/j.jaci.2016.09.015
52. Osei ET, B Mostaço-Guidolin L, Hsieh A, Warner SM, Al-Fouadi M et al. Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts: Implications for asthma. Scientific Reports 2020; 10 (1): 1-14. https://doi.org/10.1038/s41598-020-65567-z
53. Zhang FL, Gao HQ, Wu JM, Ma YB, You BA et al. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced glycation end products in endothelial cells. Journal of Cardiovascular Pharmacology 2006; 48 (2): 47-53. https://doi.org/10.1097/01. fjc.0000242058.72471.0c
54. Dorecka M, Siemianowicz K, Francuz T, Garczorz W, Chyra A et al. Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells. Pharmacological Reports 2013; 65 (4): 884-90. https://doi.org/10.1016/s1734-1140(13)71069-7
55. Iwashima Y, Eto M, Hata A, Kaku K, Horiuchi S et al. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages.
Biochemical and Biophysical Research Communications 2000; 277 (2): 368-380. https://doi.org/10.1006/bbrc.2000.3685
56. Pertyńska-Marczewska M, Kiriakidis S, Wait R, Beech J, Feldmann M et al. Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine 2004; 28 (1): 35-47. https://doi.org/10.1016/j.cyto.2004.06.006

APA	BİRBEN E, SAHINER U (2023). Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. , 160 - 170. 10.55730/1300-0144.5569
Chicago	BİRBEN ESRA,SAHINER Umit Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. (2023): 160 - 170. 10.55730/1300-0144.5569
MLA	BİRBEN ESRA,SAHINER Umit Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. , 2023, ss.160 - 170. 10.55730/1300-0144.5569
AMA	BİRBEN E,SAHINER U Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. . 2023; 160 - 170. 10.55730/1300-0144.5569
Vancouver	BİRBEN E,SAHINER U Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. . 2023; 160 - 170. 10.55730/1300-0144.5569
IEEE	BİRBEN E,SAHINER U "Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma." , ss.160 - 170, 2023. 10.55730/1300-0144.5569
ISNAD	BİRBEN, ESRA - SAHINER, Umit. "Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma". (2023), 160-170. https://doi.org/10.55730/1300-0144.5569

APA	BİRBEN E, SAHINER U (2023). Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. Turkish Journal of Medical Sciences, 53(1), 160 - 170. 10.55730/1300-0144.5569
Chicago	BİRBEN ESRA,SAHINER Umit Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. Turkish Journal of Medical Sciences 53, no.1 (2023): 160 - 170. 10.55730/1300-0144.5569
MLA	BİRBEN ESRA,SAHINER Umit Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. Turkish Journal of Medical Sciences, vol.53, no.1, 2023, ss.160 - 170. 10.55730/1300-0144.5569
AMA	BİRBEN E,SAHINER U Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. Turkish Journal of Medical Sciences. 2023; 53(1): 160 - 170. 10.55730/1300-0144.5569
Vancouver	BİRBEN E,SAHINER U Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma. Turkish Journal of Medical Sciences. 2023; 53(1): 160 - 170. 10.55730/1300-0144.5569
IEEE	BİRBEN E,SAHINER U "Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma." Turkish Journal of Medical Sciences, 53, ss.160 - 170, 2023. 10.55730/1300-0144.5569
ISNAD	BİRBEN, ESRA - SAHINER, Umit. "Determination of the effects of advanced glycation end products receptor polymorphisms and its activation on structural cell responses and inflammation in asthma". Turkish Journal of Medical Sciences 53/1 (2023), 160-170. https://doi.org/10.55730/1300-0144.5569